- Home
- OLMA
as 01-17-2025 4:00pm EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 420.2M | IPO Year: | 2020 |
| Target Price: | $26.25 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.60 - $16.78 | Next Earning Date: | 03-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | OLMA | 10% Owner | Jan 8 '25 | Buy | $5.76 | 300,000 | $1,727,370.00 | 7,800,000 | |
| Graham G. Walmsley | OLMA | Director | Dec 13 '24 | Buy | $6.75 | 1,401,522 | $9,460,273.50 | 1,408,875 | |
| Graham G. Walmsley | OLMA | Director | Dec 13 '24 | Sell | $6.75 | 1,401,522 | $9,460,273.50 | 0 | |
| Harmon Cyrus | OLMA | Director | Dec 9 '24 | Sell | $9.14 | 16,393 | $147,955.81 | 764,140 | |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Dec 9 '24 | Sell | $9.14 | 26,066 | $234,916.00 | 611,947 | |
| Kovacs Shane William Charles | OLMA | CH. OPERATING & FINANCIAL OFF. | Dec 9 '24 | Sell | $9.14 | 35,159 | $316,703.45 | 543,955 | |
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Dec 9 '24 | Sell | $9.14 | 27,805 | $250,455.83 | 130,031 | |
| Bohen Sean | OLMA | PRESIDENT AND CEO | Dec 9 '24 | Sell | $9.14 | 109,502 | $986,365.11 | 241,662 |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Top Midday Decliners
MT Newswires
13 days ago
Olema Pharmaceuticals Files Shelf for 2 Equity Offerings
GlobeNewswire
16 days ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
17 days ago
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
a month ago
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
MT Newswires
a month ago
Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate
GlobeNewswire
a month ago
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
GlobeNewswire
2 months ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare OLMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.